Analysts’ Recent Ratings Changes for Ultragenyx Pharmaceutical (RARE)

A number of research firms have changed their ratings and price targets for Ultragenyx Pharmaceutical (NASDAQ: RARE):

  • 11/23/2018 – Ultragenyx Pharmaceutical was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 11/15/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 11/15/2018 – Ultragenyx Pharmaceutical was given a new $59.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 11/14/2018 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 11/8/2018 – Ultragenyx Pharmaceutical was upgraded by analysts at Citigroup Inc from a “sell” rating to a “neutral” rating. They now have a $54.00 price target on the stock, up previously from $46.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 11/7/2018 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Canaccord Genuity from $90.00 to $75.00. They now have a “buy” rating on the stock.
  • 11/6/2018 – Ultragenyx Pharmaceutical had its price target raised by analysts at Raymond James from $53.00 to $57.00. They now have a “buy” rating on the stock.
  • 10/29/2018 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Citigroup Inc from $49.00 to $46.00. They now have a “sell” rating on the stock.
  • 10/29/2018 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Wedbush from $90.00 to $88.00. They now have an “outperform” rating on the stock.
  • 10/29/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 10/29/2018 – Ultragenyx Pharmaceutical was given a new $70.00 price target on by analysts at Morgan Stanley. They now have a “hold” rating on the stock.
  • 10/29/2018 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Credit Suisse Group AG from $78.00 to $59.00. They now have a “hold” rating on the stock.
  • 10/29/2018 – Ultragenyx Pharmaceutical had its price target lowered by analysts at SunTrust Banks, Inc. from $83.00 to $54.00. They now have a “buy” rating on the stock.
  • 10/27/2018 – Ultragenyx Pharmaceutical was given a new $68.00 price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 10/26/2018 – Ultragenyx Pharmaceutical had its price target lowered by analysts at Piper Jaffray Companies to $70.00. They now have an “overweight” rating on the stock.
  • 10/26/2018 – Ultragenyx Pharmaceutical was given a new $70.00 price target on by analysts at Raymond James. They now have a “buy” rating on the stock.
  • 10/19/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/12/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 10/9/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/8/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of  Q3 earnings release.”
  • 10/7/2018 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $86.00 price target on the stock. They wrote, “Ahead of the pending Phase 3 results for UX007 (trihep) in Glut1 DS expected sometime this quarter, we sifted through early data and market sizing assumptions to frame expectations and potential upside/downside on the event. Bottom line, while directly comparable data are limited to say the least (most similar pilot study only had an N of 6 and Phase 2 trials evaluated different endpoints), we believe a positive read- out is the most likely outcome given proof of concept data combined with seemingly reasonable powering assumptions. Between the recent pullback in shares (15% since 9/25) and our sense that this opportunity is not well understood by the market, we see risk/reward slightly skewed to the upside. Maintain OW.””
  • 10/3/2018 – Ultragenyx Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $86.00 price target on the stock. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However,developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. “
  • 9/29/2018 – Ultragenyx Pharmaceutical was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.

Ultragenyx Pharmaceutical stock opened at $53.28 on Monday. Ultragenyx Pharmaceutical Inc has a one year low of $41.67 and a one year high of $90.98. The company has a market capitalization of $2.69 billion, a P/E ratio of -7.10 and a beta of 2.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($1.74) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.94) by $0.20. The firm had revenue of $11.80 million during the quarter, compared to the consensus estimate of $11.97 million. Ultragenyx Pharmaceutical had a negative return on equity of 40.10% and a negative net margin of 508.70%. The company’s quarterly revenue was up 5800.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.87) earnings per share. Analysts predict that Ultragenyx Pharmaceutical Inc will post -3.99 EPS for the current year.

In related news, CFO Shalini Sharp sold 6,700 shares of the stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total transaction of $603,469.00. Following the sale, the chief financial officer now owns 56,828 shares of the company’s stock, valued at approximately $5,118,497.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William Aliski sold 6,000 shares of the stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $55.67, for a total value of $334,020.00. Following the sale, the director now directly owns 72,610 shares in the company, valued at approximately $4,042,198.70. The disclosure for this sale can be found here. Insiders sold a total of 32,250 shares of company stock valued at $2,354,669 in the last 90 days. Corporate insiders own 8.40% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Advisors Asset Management Inc. purchased a new stake in Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $181,000. Pacer Advisors Inc. purchased a new position in Ultragenyx Pharmaceutical during the third quarter valued at $222,000. Gideon Capital Advisors Inc. purchased a new position in Ultragenyx Pharmaceutical during the third quarter valued at $303,000. Janney Montgomery Scott LLC purchased a new position in Ultragenyx Pharmaceutical during the third quarter valued at $313,000. Finally, Paloma Partners Management Co bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth $343,000. Hedge funds and other institutional investors own 95.39% of the company’s stock.

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Featured Article: Day Trading

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply